SOUVIK BANERJEE

Mr. SOUVIK BANERJEE


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
SBSOUVIK BANERJEE
SOUVIK BANERJEE
KMKaustav Majumder
Kaustav Majumder
GGGerardo Jose Gutierrez
Gerardo Jose Gutierrez
DGDebkishore Gupta
Debkishore Gupta
Bharti MittalBharti Mittal
Bharti Mittal
The novel Corona Virus Disease 2019 (COVID-19) pandemic has set the fatality rates ablaze across the world. So, to combat this disease, we have designed a multi-epitope vaccine from various proteins of Severe Acute Respiratory Syndrome Corona virus 2 (SARS-CoV-2) with an immuno-informatics approach, validated in silico to be stable, non-allergic and antigenic. Cytotoxic T-cell, helper T-cell, and B-cell epitopes were computationally predicted from six conserved protein sequences among four viral strains isolated across the world. The T-cell epitopes, overlapping with the B-cell epitopes, were included in the vaccine construct to assure the humoral and cell-mediated immune response. The beta-subunit of cholera toxin was added as an adjuvant at the N-terminal of the construct to increase immunogenicity. Interferon-gamma inducing epitopes were even predicted in the vaccine. Molecular docking and binding energetics studies revealed strong interactions of the vaccine with immune-stimulatory toll-like receptors (TLR) −2, 3, 4. Molecular dynamics simulation of the vaccine ensured in vivo stability in the biological system. The immune simulation of vaccine evinced elevated immune response. The efficient translation of the vaccine in an expression vector was assured utilizing in silico cloning approach. Certainly, such a vaccine construct could reliably be effective against COVID-19.

10 March 2018 in International Journal of Current Microbiology and Applied Sciences
Verified
Closed access
SBSOUVIK BANERJEE
SOUVIK BANERJEE
AGAbhishek Goswami
Abhishek Goswami
ADAnanya Datta
Ananya Datta
APAnish Pyne
Anish Pyne
ANAnjoom Nikhat
Anjoom Nikhat
BGBodhisattwa Ghosh
Bodhisattwa Ghosh

15 August 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
SBSOUVIK BANERJEE
SOUVIK BANERJEE
SCSoham Chakraborty
Soham Chakraborty
KMKaustav Majumder
Kaustav Majumder
Novel peptide therapeutics have been the cardinal part of modern-day research. Such therapies are being incorporated to prevent the adverse effects of globally emerging multi-drug resistant bacteria and various chronic human diseases which pose a great risk to the present world. In this study, we have designed a novel peptide therapy involving archaeal antimicrobial peptides. In silico predictions assign the peptide construct to be antigenic, non-allergenic, non-toxic and having stable physicochemical properties. The secondary and tertiary structures of the construct were predicted. The tertiary structure was refined for improving the quality of the predicted model. Computational tools predicted intracellular receptors in Escherichia coli , Klebsiella pneumoniae and the human body to be possible binding targets of the construct. In silico docking of modelled peptide with predicted targets, showed prominent results against targets for complex human diseases and that of bacterial infections. The stability of those docked complexes was confirmed with computational studies of conformational dynamics. Certainly, the designed peptide could be a potent therapeutic against multi-drug resistant bacteria as well as several human diseases.

7 April 2022 in Biologia
Verified
Journal Article
Closed access
PDF file
SBSOUVIK BANERJEE
SOUVIK BANERJEE
SCSoham Chakraborty
Soham Chakraborty
KMKaustav Majumder
Kaustav Majumder